Gilgamesh Pharmaceuticals is a clinical-stage neuroscience biotech developing innovative, best-in-class new chemical entities (NCEs) that transform the treatment paradigm of psychiatric diseases, moving away from symptom management towards rapid-acting and durable therapies. ...
所属公司:Gilgamesh Pharmaceuticals, Inc. 当前融资轮次:B++轮 成立日期:2019-01-01 所属地:美国 简介:Gilgamesh Pharmaceuticals是一家专注于心理健康科学的生物科技公司,提供用于迷幻药,新型精神药物,抑郁症,焦虑症和与压力有关的疾病的药物。 简介:Gilgamesh Pharmaceuticals是一家专注于心理健康科学的生物科技公司,...
企业简称 Gilgamesh Pharmaceuticals企业全称 Gilgamesh Pharmaceuticals 成立时间 - 融资阶段 战略投资 市值/估值 -人员规模 - 一级行业 医疗健康企业网址 https://www.gilgameshpharmaceutical.com/ 运营状态 运营中公司类型 实体企业 一句话简介 美国精神障碍疾病药物生产商 企业介绍 Gilgamesh Pharmaceuticals是一家美国精...
Gilgamesh Pharmaceuticals is a clinical-stage neuroscience biotech that specializes in the development of psychiatric disease treatments. It focuses on creating therapies that aim to improve traditional symptom management. Gilgamesh Pharmaceuticals primarily serves the healthcare and pharmaceutical sectors, with...
前两天,艾伯维$艾伯维公司(ABBV)$20亿美元购买纽约生物技术公司 Gilgamesh Pharmaceuticals正在开发的新精神药物,这是一种被叫做神经塑性剂(neuroplastogens)的迷幻药物,有治疗多种CNS疾病的潜力。第一代神经塑性剂比如氯胺酮或裸盖菇素,都有滥用倾向、致幻等风险,而艾伯维买的这个新药据说能最大限度减少第一代化合物的...
艾伯维与Gilgamesh Pharmaceuticals达成合作协议,2024年5月13日,艾伯维与Gilgamesh Pharmaceuticals达成合作协议,利用后者在新型神经功能重塑因子(neuroplastogens)的
Gilgamesh Pharmaceuticals has 13 investors. National Institute on Drug Abuse invested in Gilgamesh Pharmaceuticals's Grant funding round. First funding Last Funding Investor Rounds Board Seats Type Location 3/14/2024 3/14/2024 National Institute on Drug Abuse 1 Grant Government United States 5/6/2021...